Summary of Key Points Core Viewpoint - Sarepta Therapeutics (SRPT) has seen a 14.1% increase in share price over the past four weeks, closing at $124.47, with a potential upside of 48% based on Wall Street analysts' mean price target of $184.15 [1] Price Target Analysis - The average of 20 short-term price targets ranges from a low of $75 to a high of $217, with a standard deviation of $32.08, indicating variability in estimates [2] - The lowest estimate suggests a decline of 39.7%, while the highest indicates a potential upside of 74.3% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [7] Earnings Estimates and Analyst Sentiment - Analysts are increasingly optimistic about SRPT's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - Over the last 30 days, one estimate has increased, leading to a 4.7% rise in the Zacks Consensus Estimate for the current year [10] - SRPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11] Caution on Price Targets - While consensus price targets are popular among investors, they may not reliably indicate actual stock price movements, and should be approached with skepticism [5][8] - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [6]

Shares of Sarepta Therapeutics (SRPT) rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals .ARWR Deal Expands Sarepta’s PipelinePer the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical development. These programs are being developed against a broad range of genetic diseases in ...

Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $185.45 indicates a potential upside of 42.1%.The mean estimate comprises 20 short-term price targets with a standard deviation of $31.14. While the lowest estimate of $80 indicates a 38.7% decline from the ...

Company Overview - Sarepta Therapeutics reported earnings of 7 cents per share for Q2 2024, surpassing the Zacks Consensus Estimate of breakeven earnings, compared to a loss of 27 cents in the same period last year [2] - Total revenues reached $362.9 million, reflecting a 39% year-over-year increase, although it fell short of the Zacks Consensus Estimate of $386.9 million [3] - Product revenues increased by 51% year over year to $360.5 million, driven by heightened demand for marketed products, but missed the consensus estimate of $373 million [4] Product Performance - Sales from Elevidys amounted to $121.7 million, down from $133.9 million in Q1 2024, missing estimates of $143 million and $150 million due to a restrictive FDA label [5] - Contract manufacturing collaboration revenues from Elevidys supplied to Roche were approximately $2.4 million, a significant decrease from $22.3 million in the previous year [6] Expense Management - Adjusted R&D expenses totaled $153.9 million, down 27% year over year, primarily due to the capitalization of expenses related to Elevidys [7] - Adjusted selling, general, and administrative expenses rose by 17% year over year to $106.0 million, driven by increased professional service expenses for Elevidys' launch [7] Financial Guidance - Management anticipates a quarter-over-quarter increase in Elevidys sales by nearly one-third in Q3 2024, followed by a doubling of revenues from Q3 to Q4 [8] - For 2025, the company expects net product revenues to be in the range of $2.9 billion to $3.1 billion [8] Market Sentiment - There has been a downward trend in estimates revisions, with the consensus estimate shifting by -112.78% [9] - Sarepta Therapeutics currently holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [11] Industry Comparison - Sarepta operates within the Zacks Medical - Biomedical and Genetics industry, where Halozyme Therapeutics has seen a 12.1% increase in stock price over the past month [12] - Halozyme reported revenues of $231.35 million, a year-over-year increase of 4.7%, with an EPS of $0.91 compared to $0.74 a year ago [13]

Core Insights - Sarepta Therapeutics (SRPT) experienced a significant decline after reaching a three-year high of $173.25 on June 21, closing lower in six of the last seven weeks, but has shown a positive bounce off the $125 level this week, maintaining a 36% year-to-date gain [1] Stock Performance - The stock's recent pullback has brought it within one standard deviation of its 126-day moving average, with historical data indicating that similar occurrences have led to a 75% chance of the stock being higher one month later, averaging an 11.1% gain [2] - If the stock continues to rise from its current price of $131.21, it could surpass the $145 mark, which was a support level last month [2] Analyst Sentiment - Despite some disappointment with the latest earnings report, analysts remain optimistic about Sarepta Therapeutics, with 17 out of 19 analysts maintaining "buy" ratings [3] - Following a global selloff, Piper Sandler has categorized Sarepta as one of eight "high-quality" defense stocks in the biopharma sector amid market volatility [3]

Both of these biotechs are highly innovative companies. We are still in a bull market, but the biotech industry, as measured by the SPDR S&P Biotech ETF (an industry benchmark), hasn't been keeping up with broader equities this year. That's no reason to avoid biotech stocks -- after all, some are doing just fine. That's the case with Vertex Pharmaceuticals (VRTX -0.41%) and Sarepta Therapeutics (SRPT 0.87%). Although these drugmakers continue to perform well, both look to have plenty of upside. Let's find o ...

A downtrend has been apparent in Sarepta Therapeutics (SRPT) lately with too much selling pressure. The stock has declined 10.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicat ...

Sarepta Therapeutics, Inc. (SRPT) posted earnings of 7 cents per share in second-quarter 2024, beating the Zacks Consensus Estimate of breakeven earnings. In the year-ago period, the company posted a loss of 27 cents. The loss included depreciation and amortization expenses and stock-based compensation expenses. Adjusted earnings per share in the quarter stood at 44 cents against the year-ago period's adjusted loss of $1.01 per share. Sarepta recorded total revenues of $362.9 million, up 39% year over year. ...

For the quarter ended June 2024, Sarepta Therapeutics (SRPT) reported revenue of $362.93 million, up 38.9% over the same period last year. EPS came in at $0.07, compared to -$0.27 in the year-ago quarter. ...

Financial Data and Key Metrics Changes - For Q2 2024, the company recorded total revenues of $362.9 million, an increase of $101.7 million compared to $261.2 million in Q2 2023 [39] - Net product revenue for ELEVIDYS was $121.7 million, while the PMO franchise generated approximately $238.8 million, showing modest growth [40][41] - The company reported a GAAP net income of $6.5 million for Q2 2024, compared to a net loss of $23.9 million in Q2 2023 [41] Business Line Data and Key Metrics Changes - The Duchenne franchise generated net product revenues of approximately $361 million in Q2 2024, a 51% increase year-over-year [7] - ELEVIDYS achieved $121.7 million in net product revenue, while the PMO franchise saw revenues of roughly $239 million, indicating slight growth [10][11] - Individual net product sales included $129.8 million for EXONDYS 51, $77.4 million for AMONDYS 45, and $31.6 million for VYONDYS 53 [40] Market Data and Key Metrics Changes - The company anticipates net product revenue for 2025 to be between $2.9 billion and $3.1 billion, indicating strong market potential [9][17] - The company is experiencing robust demand from the Duchenne patient population, with significant interest in ELEVIDYS following its label expansion [12][13] Company Strategy and Development Direction - The company aims to treat the prevalent Duchenne population throughout the decade, transitioning to the incident population in 2030-2031 [9][53] - The focus remains on expanding access to ELEVIDYS and ensuring patient safety while navigating the complexities of gene therapy launches [19][20] - The company is committed to advancing its pipeline, including therapies for limb-girdle muscular dystrophy and other rare diseases [28][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the launch of ELEVIDYS, noting that the early demand signals are positive and that the company is well-prepared to meet patient needs [8][12] - The company expects moderate revenue growth in Q3 2024, with strong growth anticipated in Q4 2024 and beyond [8][17] - Management highlighted the importance of patient safety and education in the successful integration of new therapies into treatment regimens [19][20] Other Important Information - The company achieved cash flow positivity for the first time in its history and expects to maintain this status moving forward [35] - A termination of a development and supply agreement related to an adherent manufacturing process is expected to incur additional R&D expenses of approximately $55 million to $65 million [37][38] Q&A Session Summary Question: What is the actual bottleneck in the patient journey from prescription to drug administration? - Management clarified that there is no fundamental bottleneck, and the typical process from start form to infusion takes about three to five months, which is standard for such therapies [44][45][49] Question: How should the market think about the growth trajectory and peak sales for the upcoming years? - Management indicated that peak year sales will occur significantly in the back half of this decade, with a focus on treating the prevalent population throughout the decade [52][53] Question: What are the early launch data supporting the revenue guidance for 2025? - Management expressed confidence based on extensive experience with previous launches and current demand indicators, aligning with external market expectations [56][58]